Iovance Shareholders Should Contact Shareholder Rights Firm Regarding Potential Legal Claims

NEW YORK, May 17, 2025 /PRNewswire/ — Julie & Holleman LLP, a top-tier shareholder rights firm, is investigating potential claims against Iovance  Biotherapeutics, Inc. (Nasdaq: IOVA) and its executives for recent losses suffered by the company’s stockholders. For a free consultation, please visit https://julieholleman.com/iovance-biotherapeutics-inc/. You may also contact partner Scott Holleman at (929) 415-1020 or by… Continue reading Iovance Shareholders Should Contact Shareholder Rights Firm Regarding Potential Legal Claims

Ibotta Shareholders Should Contact Shareholder Rights Firm Regarding Potential Legal Claims

NEW YORK, May 17, 2025 /PRNewswire/ — Julie & Holleman LLP, a top-tier shareholder rights firm, is investigating potential claims against Ibotta, Inc. (NYSE: IBTA) and its executives for recent losses suffered by the company’s stockholders. For a free consultation, please visit https://julieholleman.com/ibotta-inc/. You may also contact partner Scott Holleman at (929) 415-1020 or by… Continue reading Ibotta Shareholders Should Contact Shareholder Rights Firm Regarding Potential Legal Claims

Skechers Shareholders Unhappy with Merger Should Contact Shareholder Rights Firm Regarding Potential Legal Claims

NEW YORK, May 17, 2025 /PRNewswire/ — Julie & Holleman LLP, a top-tier shareholder rights firm, is investigating the acquisition of Skechers U.S.A., Inc. (NYSE: SKX) by global investment firm 3G Capital. The law firm has already uncovered conflicts of interest and believes the deal price is too low. For a free consultation, please visit https://julieholleman.com/skechers-usa-inc/.… Continue reading Skechers Shareholders Unhappy with Merger Should Contact Shareholder Rights Firm Regarding Potential Legal Claims

TASK ALERT: TaskUs Shareholders Interesting In Pursuing Potential Claims Should Contact Shareholder Rights Firm Regarding Proposed Buyout

NEW YORK, May 17, 2025 /PRNewswire/ — Julie & Holleman LLP, a top-tier shareholder rights firm, is investigating the proposed buyout of TaskUs, Inc. (Nasdaq: TASK) by the company’s three largest shareholders: private equity firm Blackstone and co-founders Bryce Maddock and Jaspar Weir. For a free consultation, please visit https://julieholleman.com/taskus-inc/. You may also contact partner… Continue reading TASK ALERT: TaskUs Shareholders Interesting In Pursuing Potential Claims Should Contact Shareholder Rights Firm Regarding Proposed Buyout

IOVA Shareholder Alert: Robbins LLP Informs Investors of the Iovance Biotherapeutics, Inc. Class Action Lawsuit

SAN DIEGO, May 16, 2025 /PRNewswire/ — Robbins LLP informs stockholders that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) securities between May 9, 2024 and May 8, 2025. Iovance is a commercial-stage biopharmaceutical company which develops and commercializes cell therapies for… Continue reading IOVA Shareholder Alert: Robbins LLP Informs Investors of the Iovance Biotherapeutics, Inc. Class Action Lawsuit

TCL и MediaMarktSaturn расширяют стратегическое партнерство по розничной торговле на Германию

ПАРИЖ, 17 мая 2025 г. /PRNewswire/ — Сегодня TCL, глобальный бренд сверхбольших телевизоров № 1 [1] и бренд телевизоров Mini LED № 1 [2], объявил о расширении своего стратегического партнерства по розничной торговле с MediaMarktSaturn Retail Group, европейским ритейлером потребительской электроники номер один, теперь и на Германию. Новейшая линейка TCL, уже предлагаемая в отдельных странах MediaMarkt, с мая… Continue reading TCL и MediaMarktSaturn расширяют стратегическое партнерство по розничной торговле на Германию

Silver Star Properties REIT Announces Turnaround Success of Southern Star Self Storage and Strategic Momentum Toward Self-Storage Platform Expansion

EXECUTIVE HIGHLIGHTS Plano, TX: NOI more than doubled—from $15,850 in Q1 2024 to $35,307 in Q1 2025, as occupancy rose over 4%. Montrose StormKing, CO: NOI tripled from $16,967 in Q1 2024 to $52,370 in Q1 2025. George West, TX: Occupancy improved from 54.3% to 62.8%, a 9% gain under the new management model. HOUSTON,… Continue reading Silver Star Properties REIT Announces Turnaround Success of Southern Star Self Storage and Strategic Momentum Toward Self-Storage Platform Expansion

Consensus 2025 Wraps in Toronto With Eric Trump

Crypto’s “Big Tent” event has wrapped in Toronto as high-profile figures across business, technology and government gathered to discuss crypto’s regulatory liberalization and rising adoption. In 2026, Consensus will be hosted in Hong Kong (February) and Miami (May). TORONTO, May 16, 2025 /PRNewswire/ — Consensus 2025, the world’s longest-running and most influential gathering for the… Continue reading Consensus 2025 Wraps in Toronto With Eric Trump

One Year Into Their Successful Collaboration the Texas Southern University Board of Regents and President Look To The Future, Together

HOUSTON, May 16, 2025 /PRNewswire/ — One year ago today, Texas Southern University’s Board of Regents voted unanimously to appoint James W. Crawford III, Vice Admiral and Judge Advocate General of the Navy (Ret.), as TSU’s 14th President. Continue Reading J.W. Crawford III Vice Admiral, JAGC, U.S. Navy (Retired) President, Texas Southern University Texas Southern… Continue reading One Year Into Their Successful Collaboration the Texas Southern University Board of Regents and President Look To The Future, Together

Statement from the Alzheimer’s Drug Discovery Foundation (ADDF) on FDA Approval of the First Blood Test to Aid in Alzheimer’s Diagnosis

NEW YORK, May 16, 2025 /PRNewswire/ — Today, the FDA’s approved the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio, marking a pivotal moment in the fight against Alzheimer’s disease. This is the first blood test authorized to aid in the diagnosis of Alzheimer’s—ushering in a new era of care, alongside recent approvals of disease-modifying therapies. “Today’s… Continue reading Statement from the Alzheimer’s Drug Discovery Foundation (ADDF) on FDA Approval of the First Blood Test to Aid in Alzheimer’s Diagnosis